Xetra
18.11.25 | 17:16
295,10 Euro
+0,12 % +0,35
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 297,40 | 298,00 | 23:00 | |
| 295,45 | 297,45 | 22:01 |
► 18.11.: | | | | | | |
| |
► 17.11.: | | | | | | | | |
► Aktueller AMGEN Börsenkurs + Xetra-Orderbuch
► 17.11.: | | | | | | | | |
► Aktueller AMGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 295,45 | 60 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 120 | 295,00 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 120 | 0,500 | 60 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:16:54 | 295,10 | 9 |
| 17:16:47 | 295,10 | 8 |
| 16:20:28 | 294,15 | 5 |
| 15:36:19 | 293,35 | 6 |
| 15:36:19 | 293,35 | 21 |
| 14:56:10 | 295,10 | 2 |
| 14:56:10 | 295,15 | 48 |
| 14:44:35 | 295,75 | 2 |
| 14:40:22 | 295,75 | 9 |
| 14:40:22 | 295,75 | 3 |
| 13:37:37 | 294,85 | 1 |
| 13:11:22 | 295,00 | 5 |
| 11:55:03 | 295,20 | 20 |
| 11:38:41 | 293,90 | 1 |
| 10:52:14 | 295,15 | 40 |
| 10:43:59 | 295,05 | 2 |
| 10:43:59 | 294,55 | 13 |
| 10:42:03 | 295,20 | 20 |
| 10:06:54 | 296,05 | 1 |
| Tagesumsatz Xetra | +0,35 +0,12 % | 353 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AMGEN Aktie jetzt für 0€ handeln | |||||
| 16:26 | Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data | 11 | Insider Monkey | ||
| Mo | Amgen reports positive results from landmark cardiovascular study | 14 | PMLiVE | ||
| Fr | Survey reveals 'cardiology deserts' at heart of Amgen-backed campaign | 6 | FiercePharma | ||
| Fr | Sell Alert: Rachna Khosla Cashes Out $299K In Amgen Stock | 6 | Benzinga.com | ||
| Fr | Amgen EVP Sold $2.32M In Company Stock | 8 | Benzinga.com |
1 2 3 4 5 Weiter >>
329 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:06 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 18:31 | XFRA HDP1: WIEDERAUFNAHME/RESUMPTION | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14:36 | Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer | GlobeNewswire (Europe) | RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov.... ► Artikel lesen | |
| 17:38 | Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference... ► Artikel lesen | |
| 17:12 | Insmed Incorporated: European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union | PR Newswire | - Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei -
- BRINSUPRI Is a First-in-Disease, First-in-Class DPP1... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC finden Sie auf Wallstreet Online.